Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 17, 2018- BELVIQ did not increase incidence of cardiovascular events in study of 12,000 obese and overweight patients
Eisai Inc. announced positive topline results from the CAMELLIA-TIMI 61 cardiovascular outcome trial. This 12,000 patient study of BELVIQ® (lorcaserin HCl) CIV 10 mg twice-daily was conducted at...
Jul 9, 2018Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today the results of the BAN2401 Phase II clinical study, Study 201(ClinicalTrials.gov identifier NCT01767311), will be...
-
Jul 5, 2018- The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer's disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulated in the brain
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
-
Jul 2, 2018Presentation includes data from first-ever Phase 3 head-to-head superiority comparison vs zolpidem ER in patients with a sleep-wake disorder
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD "Purdue Pharma") today announced that they will present data on their investigational...
-
Jun 5, 2018Studies measured postural stability after middle-of-the-night awakening and next morning compared to zolpidem ER, as well as next-morning driving performance
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today presented the results of two key Phase 1 clinical studies of their...